Sensyne Health PLC (LON:SENS – Get Free Report)’s stock price fell 33.3% during trading on Friday . The company traded as low as GBX 0.16 ($0.00) and last traded at GBX 0.35 ($0.00). 4,449,142 shares were traded during trading, an increase of 29% from the average session volume of 3,449,819 shares. The stock had previously […]
Sensyne Health PLC (LON:SENS – Get Free Report)’s share price dropped 33.3% during trading on Friday . The company traded as low as GBX 0.16 ($0.00) and last traded at GBX 0.35 ($0.00). Approximately 4,449,142 shares were traded during mid-day trading, an increase of 29% from the average daily volume of 3,449,819 shares. The stock […]
Sensyne Health PLC (LON:SENS – Get Rating) shares were down 33.3% on Thursday . The company traded as low as GBX 0.16 ($0.00) and last traded at GBX 0.35 ($0.00). Approximately 4,449,142 shares changed hands during mid-day trading, an increase of 29% from the average daily volume of 3,449,819 shares. The stock had previously closed […]
Sensyne Health PLC (LON:SENS – Get Rating) shares dropped 33.3% during mid-day trading on Tuesday . The stock traded as low as GBX 0.16 ($0.00) and last traded at GBX 0.35 ($0.00). Approximately 4,449,142 shares changed hands during mid-day trading, an increase of 29% from the average daily volume of 3,449,819 shares. The stock had […]
12 March 2021 | 09:39am
StockMarketWire.com - Clinical AI technology company Sensyne has signed a £470,000 agreement with the Department of Health & Social Care (DHSC) to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The MagnifEye system is a software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests, including lateral flow tests.
The agreement with the DHSC follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.